Mark Sostek
Research Subjects
Research Interests
Mark Sostek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ali Cimen
AstraZeneca, Cambridge, UK
2 shared publications- Khanh Bui
Duke University
2 shared publications - Diansong Zhou
Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA
1 shared publication Fahua She
AstraZeneca Pharmaceuticals Gaithersburg MD USA
1 shared publication- J. Russell Teagarden
Epstein Health, Woodcliff Lake, NJ, USA.
1 shared publication - Jan Tack
Translational Research Center for Gastrointestinal Disorders (TARGID) University of Leuven Leuven Belgium
1 shared publication
Latest Publications
- Open Access
- 8 February 2017
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (3) , 725-731
When People with Opioid-Induced Constipation Speak: A Patient Survey
Opioid-induced constipation (OIC) is a common consequence of opioid use for chronic pain. OIC creates problems for patients independent of their pain syndromes, in addition to threatening pain treatment effectiveness. Healthcare practitioners need to be alert to how patients talk about OIC so that it is not missed. Using a survey mechanism, we sought patient expressions of the personal impact OIC imposes on how they are able to live their lives and on meanings that symptom relief would produce.
- 8 February 2017
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (3) , 725-731
Open AccessWhen People with Opioid-Induced Constipation Speak: A Patient Survey
Opioid-induced constipation (OIC) is a common consequence of opioid use for chronic pain. OIC creates problems for patients independent of their pain syndromes, in addition to threatening pain treatment effectiveness. Healthcare practitioners need to be alert to how patients talk about OIC so that it is not missed. Using a survey mechanism, we sought patient expressions of the personal impact OIC imposes on how they are able to live their lives and on meanings that symptom relief would produce.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S538
Su1597 Naloxegol for Opioid-Induced Constipation: Mechanism of Action and Clinical Implications
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S538
Su1597 Naloxegol for Opioid-Induced Constipation: Mechanism of Action and Clinical Implications
- 24 February 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (8) , 1019-1027
Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol
Naloxegol, a peripherally acting μ‐opioid receptor antagonist, was recently approved in the United States for the treatment of opioid‐induced constipation. This study evaluated the effects of CYP3A inhibition and induction on the pharmacokinetics, safety, and tolerability of naloxegol. Separate open‐label, nonrandomized, fixed‐sequence, 3‐period, 3‐treatment, crossover studies of naloxegol (25 mg by mouth [PO]) in the absence or presence of the inhibitors ketoconazole (400 mg PO) and diltiazem extended release (240 mg PO), or the inducer rifampin (600 mg PO) were conducted in healthy volunteers. Area under the curve (AUC∞) for naloxegol was increased with coadministration of either ketoconazole (12.9‐fold) or diltiazem (3.4‐fold) and decreased by 89% with coadministration of rifampin compared with AUC∞for naloxegol alone. Naloxegol was generally safe and well tolerated when given alone or coadministered with the respective CYP3A modulators; 1 subject discontinued because of elevations in liver enzymes attributed to rifampin. The exposure of naloxegol was affected substantially by ketoconazole, diltiazem, and rifampin, suggesting that it is a sensitive in vivo substrate of CYP3A4.
- 24 February 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (8) , 1019-1027
Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol
Naloxegol, a peripherally acting μ‐opioid receptor antagonist, was recently approved in the United States for the treatment of opioid‐induced constipation. This study evaluated the effects of CYP3A inhibition and induction on the pharmacokinetics, safety, and tolerability of naloxegol. Separate open‐label, nonrandomized, fixed‐sequence, 3‐period, 3‐treatment, crossover studies of naloxegol (25 mg by mouth [PO]) in the absence or presence of the inhibitors ketoconazole (400 mg PO) and diltiazem extended release (240 mg PO), or the inducer rifampin (600 mg PO) were conducted in healthy volunteers. Area under the curve (AUC∞) for naloxegol was increased with coadministration of either ketoconazole (12.9‐fold) or diltiazem (3.4‐fold) and decreased by 89% with coadministration of rifampin compared with AUC∞for naloxegol alone. Naloxegol was generally safe and well tolerated when given alone or coadministered with the respective CYP3A modulators; 1 subject discontinued because of elevations in liver enzymes attributed to rifampin. The exposure of naloxegol was affected substantially by ketoconazole, diltiazem, and rifampin, suggesting that it is a sensitive in vivo substrate of CYP3A4.
- 1 July 2014
- Published by Taylor & Francis in Pain Management
- Vol. 4 (4) , 267-276
A Description of Clinical Characteristics and Treatment Patterns Observed within Prescribed Opioid Users in Germany and the UK
To describe a cohort of new opioid users (adult noncancer patients) in terms of clinical characteristics and treatment patterns in the UK and Germany. Data used were extracted from electronic medical records databases (UK: Clinical Practice Research Database-Hospital Episode Statistics; Germany: IMS Disease Analyzer) covering the 2008-2012 period. Most eligible patients were treated with opioids for less than 6 months (UK: 78.7% and Germany: 93.7%) and indexed on weak opioids (UK: 89.5% and Germany: 88.6%). Most prescribed opioids were codeine (UK) and tramadol (Germany). Most prevalent comorbidities were dorsalgia/depression. Constipation was observed in 16.8%/17.4% (UK/Germany) of chronic users (>6 months). While both populations were highly morbid populations largely initiated on weak opioids, chronic use was less common in Germany.
- 1 July 2014
- Published by Taylor & Francis in Pain Management
- Vol. 4 (4) , 267-276
A Description of Clinical Characteristics and Treatment Patterns Observed within Prescribed Opioid Users in Germany and the UK
To describe a cohort of new opioid users (adult noncancer patients) in terms of clinical characteristics and treatment patterns in the UK and Germany. Data used were extracted from electronic medical records databases (UK: Clinical Practice Research Database-Hospital Episode Statistics; Germany: IMS Disease Analyzer) covering the 2008-2012 period. Most eligible patients were treated with opioids for less than 6 months (UK: 78.7% and Germany: 93.7%) and indexed on weak opioids (UK: 89.5% and Germany: 88.6%). Most prescribed opioids were codeine (UK) and tramadol (Germany). Most prevalent comorbidities were dorsalgia/depression. Constipation was observed in 16.8%/17.4% (UK/Germany) of chronic users (>6 months). While both populations were highly morbid populations largely initiated on weak opioids, chronic use was less common in Germany.
- 1 April 2011
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (4) , 847-854
Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers
To evaluate long-term safety of enteric-coated naproxen 500 mg and immediate-release esomeprazole magnesium 20 mg fixed-dose combination (FDC) in patients at risk of NSAID-associated upper gastrointestinal (UGI) ulcers. In this open-label, multicenter, phase III study, Helicobacter pylori-negative patients aged ≥50 years or 18–49 years with history of uncomplicated ulcer within the past 5 years, who had osteoarthritis, rheumatoid arthritis, or other condition requiring daily NSAIDs for ≥12 months received naproxen/esomeprazole twice daily for 12 months. NCT00527904. Adverse events (AEs), vital signs, physical examination, and laboratory tests. Subgroup analyses included age and low-dose aspirin (LDA) use. Predefined NSAID-associated UGI and cardiovascular AEs were analyzed. Of 239 patients treated (safety population), 135 completed ≥348 treatment days (12-month completers). AE incidence was approximately 70%; dyspepsia, constipation, upper respiratory tract infection, nausea, back pain, and contusion were most frequent (≥5% patients, either population). Treatment-related AEs occurred in 28.0% and 23.7% of patients in the safety and 12-month completer populations, respectively; 18.8% of patients withdrew due to AEs (safety population). Few serious AEs and no deaths occurred. In the safety population, AE incidence was 71.4% and 76.9% in patients aged n = 161) and ≥65 years (n = 78), respectively, and 67.6% and 75.8% in LDA users (n = 74) and non-users (n = 165), respectively. Predefined UGI and cardiovascular AEs were observed in 18.8% and 6.3% of patients, respectively, in the safety population, and 16.3% and 5.2%, respectively, in 12-month completers. Dyspepsia and hypertension were most common. Additional assessments showed no unexpected findings. Based on these outcome measures, long-term treatment with FDC naproxen/esomeprazole is not associated with any new safety issues, including predefined UGI and cardiovascular AEs, in patients requiring NSAID therapy who are at risk of UGI complications.
- 1 April 2011
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (4) , 847-854
Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers
To evaluate long-term safety of enteric-coated naproxen 500 mg and immediate-release esomeprazole magnesium 20 mg fixed-dose combination (FDC) in patients at risk of NSAID-associated upper gastrointestinal (UGI) ulcers. In this open-label, multicenter, phase III study, Helicobacter pylori-negative patients aged ≥50 years or 18–49 years with history of uncomplicated ulcer within the past 5 years, who had osteoarthritis, rheumatoid arthritis, or other condition requiring daily NSAIDs for ≥12 months received naproxen/esomeprazole twice daily for 12 months. NCT00527904. Adverse events (AEs), vital signs, physical examination, and laboratory tests. Subgroup analyses included age and low-dose aspirin (LDA) use. Predefined NSAID-associated UGI and cardiovascular AEs were analyzed. Of 239 patients treated (safety population), 135 completed ≥348 treatment days (12-month completers). AE incidence was approximately 70%; dyspepsia, constipation, upper respiratory tract infection, nausea, back pain, and contusion were most frequent (≥5% patients, either population). Treatment-related AEs occurred in 28.0% and 23.7% of patients in the safety and 12-month completer populations, respectively; 18.8% of patients withdrew due to AEs (safety population). Few serious AEs and no deaths occurred. In the safety population, AE incidence was 71.4% and 76.9% in patients aged n = 161) and ≥65 years (n = 78), respectively, and 67.6% and 75.8% in LDA users (n = 74) and non-users (n = 165), respectively. Predefined UGI and cardiovascular AEs were observed in 18.8% and 6.3% of patients, respectively, in the safety population, and 16.3% and 5.2%, respectively, in 12-month completers. Dyspepsia and hypertension were most common. Additional assessments showed no unexpected findings. Based on these outcome measures, long-term treatment with FDC naproxen/esomeprazole is not associated with any new safety issues, including predefined UGI and cardiovascular AEs, in patients requiring NSAID therapy who are at risk of UGI complications.